Generic Medicine Info
Should be taken with food.
Pre-existing maculopathy of the eye.
Special Precautions
Patient w/ G6PD deficiency, DM, haematological and GI disorders, alcoholism, porphyria, psoriasis. Renal and hepatic impairment. Childn. Pregnancy and lactation. Patient Counselling This drug may cause dizziness and blurred vision, if affected, do not drive or operate machinery. Monitoring Parameters Monitor for signs/symptoms of cardiac compromise; CBC, serum glucose, proximal muscle strength and reflexes, LFT, renal function. Perform baseline and periodic eye examination.
Adverse Reactions
Significant: Cardiomyopathy (e.g. AV block, pulmonary HTN, sick sinus syndrome), myocardial toxicity, QT interval prolongation, ventricular arrhythmia, torsade de pointes; skin reactions; bone marrow suppression (e.g. agranulocytosis, anaemia, aplastic anaemia, leucopenia, thrombocytopenia); proximal myopathy or neuromyopathy leading to progressive weakness, proximal muscle atrophy, depressed tendon reflexes, abnormal nerve conduction. Rarely, suicidal behaviour; keratopathy, retinopathy. Nervous: Ataxia, dizziness, emotional disturbance, emotional lability, headache, irritability, lassitude, nerve deafness, nervousness, nightmares, psychosis, seizures, vertigo. GI: Anorexia, diarrhoea, nausea, stomach cramps, vomiting. Resp: Bronchospasm. Hepatic: Acute hepatic failure. Rarely, hepatic insufficiency. Endocrine: Exacerbation of porphyria, wt loss. Haematologic: Haemolysis in G6PD deficiency. Ophthalmologic: Accommodation disturbance, corneal changes (e.g. transient oedema, punctuate to linear opacities, decreased sensitivity, deposits, visual disturbances, blurred vision, photophobia), decreased visual acuity, macular oedema, nystagmus, optic disk disorder, retinal pigment changes, retinal vascular disease, retinitis pigmentosa, scotoma, vision color changes, visual field defect. Otic: Tinnitus. Dermatologic: Acute generalised exanthematous pustulosis, alopecia, bleaching of hair, bullous rash, dyschromia, annulare centrifugum erythema, erythema multiforme, exacerbation of psoriasis, exfoliative dermatitis, lichenoid eruption, maculopapular rash, morbilliform rash, pruritus, skin photosensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria, purpuric rash. Immunologic: Hypersensitivity reactions (e.g. angioedema).
Potentially Fatal: Cardiac failure, severe hypoglycaemia.
Drug Interactions
Hydroxychloroquine may enhance the effect of hypoglycaemic agents. May increase plasma digoxin level. Increased risk of Torsades de pointes w/ QTc-prolonging agents (e.g. disopyramide, quinidine, amiodarone, sotalol, cisapride). Increased risk of convulsion w/ mefloquine. Antacids may interfere w/ hydroxychloroquine absorption.
ATC Classification
P01BA02 - hydroxychloroquine ; Belongs to the class of aminoquinoline antimalarials.
Disclaimer: This information is independently developed by CIMS based on hydroxychloroquine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in